Viral causes of human myocarditis

Abstract

The diagnosis of acute myocarditis is complex and challenging. The use of the Dallas criteria in the diagnosis of myocarditis is associated with poor sensitivity and specificity because of the sampling error related to the often focal distribution of the specific histological lesions in cardiac tissue and the variability in pathological interpretation. To improve histological diagnosis, additional virological evaluation of cardiac tissues is required, with immunohistochemical and polymerase chain reaction (PCR) techniques allowing identification and quantification of viral infection markers. The diagnostic gold standard is endomyocardial biopsy (EMB) with the histological Dallas criteria, in association with new immunohistochemical and PCR analyses of cardiac tissues. Using real-time PCR and reverse transcription PCR assays, parvovirus B19, Coxsackie B virus, human herpesvirus 6 (HHV-6) type B and adenovirus have been detected in 37, 33, 11 and 8% of EMB, respectively, from young adults (aged<35 years) with histologically proven acute myocarditis. Viral co-infections have also been found in 12% of acute myocarditis cases, generally parvovirus B19 plus HHV-6. Moreover, herpesviruses such as the Epstein-Barr virus or cytomegalovirus can also be associated with myocarditis after heart transplantation. During the clinical course of myocarditis, the immunohistochemical detection of enterovirus, adenovirus or parvovirus B19 capsid proteins or herpesvirus late proteins is necessary to differentiate a viral cardiac infection with replication activities from a persistent or latent cardiac infection. These new viral diagnostic approaches can lead to better identification of the aetiology of myocarditis and may therefore enable the development and evaluation of specific aetiology-directed treatment strategies.

Amiloride Is a Competitive Inhibitor of Coxsackievirus B3 RNA Polymerase

“…Coxsackievirus B3 (CVB3) is a picornavirus responsible for 14 to 32% of human myocarditis cases (1). Amiloride and its derivative 5-(N-ethyl-N-isopropyl)amiloride (EIPA) inhibit CVB3 propagation in cell culture by inhibiting viral genome replication (11).…”

DCMP as a Clinical Syndrome: Results of Nosological Diagnostics With Myocardial Biopsy and Differentiated Treatment in Virus-Positive and Virus-Negative Patients

“…Однако в целом ряде других работ была показана успешность применения ИСТ у вирус-позитивных больных в соче-тании с противовирусным лечением: у детей с острым, а также с хроническим миокардитом и синдромом ДКМП, при котором выраженный эффект ИСТ был получен независимо от персистенции вирусов в мио-карде при отсутствии улучшения в группе контроля [26,27]; у взрослых с тяжелым вирусным миокардитом [28,29]. Маастрихтский алгоритм подразумевает при одновременном выявлении вирусного генома в мио-карде и антикардиальных антител проведение проти-вовирусного лечения с последующей ИСТ [30]; анало-гичных принципов придерживается группа Andréoletti L, et al [31].…”

I Diretriz Brasileira de Miocardites e Pericardites

“…A terceira fase inicia-se no 15º dia e segue até o 90º dia após a inoculação viral, e caracteriza-se pela deposição intensa de colágeno no interstício miocárdico com fibrose miocárdica evoluindo para dilatação, disfunção e insuficiência cardíaca 28,29 .…”